Patent · US Active

Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine

US8134029B2 · kind B2 · utility

7Cited by

18References

18Claims

0Family size

Assignee

Sunovion Pharmaceuticals Inc. · US

Inventors

Thomas Jerussi · Framingham, US
Qun Kevin Fang · Wellesley, US
Mark G. Currie · Sterling, US

Key dates

Filing date	Jul 30, 2010
Grant date	Mar 13, 2012
Priority date	—
Expiry date	Jul 30, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2602/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.